You just read:

Regeneron and Sanofi Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients

News provided by

Regeneron Pharmaceuticals, Inc.

Jul 24, 2015, 03:17 ET